查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1799184

全球罕見遺傳疾病治療市場

Rare Genetic Disorders Treatment
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計2030年全球罕見基因疾病治療市場規模將達3,052億美元

全球罕見基因疾病治療市場規模預計在2024年為1,553億美元，到2030年將達到3,052億美元，在2024-2030年的分析期間內，複合年成長率為11.9%。生技藥品和生物相似藥是本報告分析的細分市場之一，預計其複合年成長率為10.2%，到分析期結束時將達到1716億美元。非生技藥品細分市場在分析期間的複合年成長率預計為14.4%。

美國市場規模估計為 408 億美元，中國市場預計複合年成長率為 11.3%

美國罕見基因疾病治療市場規模預計在2024年達到408億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到478億美元，在2024-2030年的分析期間內，複合年成長率為11.3%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為10.7%和10.4%。在歐洲，預計德國市場的複合年成長率約為8.9%。

全球罕見基因疾病治療市場—主要趨勢與促進因素摘要

罕見基因疾病為何最終受到市場關注？

罕見遺傳疾病曾因患者人數少和商業性獎勵有限而被忽視，如今已成為生物製藥創新的前沿。這些疾病病理複雜，通常缺乏有效治療方法，儘管罕見，但全球共有超過3億人受到影響。基因組學、CRISPR-Cas9基因編輯和高通量藥物篩檢的進步為標靶治療的設計創造了前所未有的機會，並將商業性模式轉向投資罕見疾病。

製藥公司越來越被吸引到這個市場，因為美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA) 和日本醫藥品醫療設備和稅額扣抵獨佔權、稅收抵免以及監管減免。這些激勵措施促進了針對Duchenne氏肌肉失養症(DMD)、脊髓性肌肉萎縮症 (SMA)、法布瑞氏症、高雪氏症和雷特氏症等疾病的藥物的積極開發。 Zolgensma（一種用於治療 SMA 的基因療法）和 Evlisdi（一種 SMN2 剪接調變器）等具有里程碑意義的核准，展現了靶向創新如何能夠攻克此前無法治癒的疾病。

新的治療方法和精準方法將如何改變照護？

基因療法、反義寡核苷酸 (ASO) 和酵素替代療法 (ERT) 正在重塑罕見遺傳疾病的治療方法。包括腺相關病毒 (AAV) 介導的遞送系統在內的基因療法，為單基因疾病提供了一次性、可能治癒的干涉措施。在可擴展生產平台和對基因表現機制更深入理解的支持下，這些治療方法正在擴展到更廣泛的適應症，例如A型血友病 A/B 和代謝症候群。

用於治療SMA和Batten病等的抗逆轉錄病毒藥物（ASO）可根據個別突變提供個人化治療。這些藥物透過改變剪接或基因轉錄來恢復缺陷的蛋白質生成，為傳統小分子藥物無法治療的疾病帶來了希望。同時，對於溶小體貯​​積症，酵素替代療法（ERT）仍然是首選治療方法，新製劑顯示出更好的生物分佈和更低的免疫抗原性。

另一項顯著的進展是在臨床前試驗中使用患者來源的誘導性多功能幹細胞(iPSC) 和類器官模型，從而能夠根據許多罕見疾病的突變特異性病因制定個人化醫療方案。此外，籃子試驗、單因子研究以及自然史資料的整合也正在改變臨床試驗設計，以適應罕見疾病患者群體規模小且分散的特性。

哪些治療領域和相關人員正在推動這項成長？

神經系統和代謝性遺傳疾病是創新和投資最集中的領域。亨廷頓舞蹈症、脊髓性肌肉萎縮症和利伯先天性黑蒙症的治療是基因治療產品線的目標，而酵素替代療法 (ERT) 繼續在高雪氏症、龐貝氏症和法布瑞氏症的治療中佔據主導地位。兒科適應症尤其突出，因為早期診斷和早期療育對於減輕疾病負擔和改善生活品質至關重要。

專注於罕見疾病的生物製藥公司，例如 BioMarin、Sarepta、Ultragenyx 和 Spark Therapeutics，正在主導臨床和商業性進程。這些公司通常得到非營利基金會、學術研究網路和患者權益組織的支持，這些組織協助進行臨床試驗招募和監管推廣。全球病患登記系統和罕見疾病聯盟正擴大被用於標準化資料收集、檢驗終點並論證加速核准性。

從區域來看，北美和歐洲憑藉著成熟的醫療體系、資金籌措生態系統和有利的政策框架，繼續主導藥物開發和監管活動。然而，亞太地區正展現出快速發展勢頭，尤其是在基因編輯研究和生技藥品生產能力方面，使其成為稀有基因療法未來的成長前沿。

是什麼推動了罕見基因疾病治療市場的成長？

罕見遺傳疾病治療市場的成長得益於科學創新、監管獎勵以及基因組檢測帶來的診斷率的提升。隨著全基因組定序變得越來越普及且價格越來越親民，先前未確診或誤診的疾病正逐漸被準確分類，從而擴大了目標治療人群。這種診斷清晰度對於輔助生殖服務（ASO）和基因治療等精準醫療方法至關重要。

諸如《孤兒藥法案》（美國）、PRIME（歐盟）和「先驅指定」（日本）等監管框架正在加速新型療法的上市時間。這些政策透過快速通道指定、更少的臨床實驗要求和更長的獨佔期，降低了開發風險，吸引了投資，並促進了創新。同時，付款人願意報銷高成本、高療效的療法（通常由長期成本補償證明），這增強了這些療法的商業性可行性。

由生物技術公司、患者權益組織和監管機構組成的協作生態系統，確保研究以患者為中心，並以結果為導向。隨著數位健康平台和遠端醫療的擴展，尤其是在核准後病患監測和真實世界證據生成方面，罕見基因疾病治療市場有望從小眾市場發展為常態化醫療，並重新定義個人化醫療的未來。

部分

藥品類型（生物製藥及生物相似藥、非生物製藥）、通路（醫院藥局、零售藥局、網路藥局）、應用（腫瘤學應用、神經系統疾病應用、心血管疾病應用、代謝性疾病應用、血液疾病應用、其他應用）

受訪公司範例

  • Alexion（AstraZeneca Rare Disease）
  • Amicus Therapeutics
  • Arcturus Therapeutics
  • Beacon Therapeutics
  • BioMarin Pharmaceutical
  • Bluebird Bio
  • CRISPR Therapeutics
  • Genomic startups（eg, GeneQuine）
  • PTC Therapeutics
  • ProQR Therapeutics
  • Rocket Pharmaceuticals
  • Sarepta Therapeutics
  • Spark Therapeutics
  • Translate Bio（Sanofi）
  • Tune Therapeutics
  • Ultragenyx Pharmaceutical
  • Vertex Pharmaceuticals
  • Zygnema/Airna etc.（RNA-editing）
  • Glycomine
  • Calliditas Therapeutics
  • Ipsen

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global Industry Analysts 沒有遵循典型的 LLM 或特定於行業的 SLM查詢，而是建立了一個從世界各地的專家收集的內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 比賽

簡介目錄
Product Code: MCP39262

Global Rare Genetic Disorders Treatment Market to Reach US$305.2 Billion by 2030

The global market for Rare Genetic Disorders Treatment estimated at US$155.3 Billion in the year 2024, is expected to reach US$305.2 Billion by 2030, growing at a CAGR of 11.9% over the analysis period 2024-2030. Biologics & Biosimilars, one of the segments analyzed in the report, is expected to record a 10.2% CAGR and reach US$171.6 Billion by the end of the analysis period. Growth in the Non-Biologics segment is estimated at 14.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$40.8 Billion While China is Forecast to Grow at 11.3% CAGR

The Rare Genetic Disorders Treatment market in the U.S. is estimated at US$40.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$47.8 Billion by the year 2030 trailing a CAGR of 11.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.7% and 10.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

Global Rare Genetic Disorders Treatment Market - Key Trends & Drivers Summarized

Why Are Rare Genetic Disorders Finally Receiving Market Attention?

Rare genetic disorders-once neglected due to small patient populations and limited commercial incentives-are now at the forefront of biopharmaceutical innovation. Characterized by complex pathologies and often lacking effective treatments, these disorders collectively affect over 300 million people worldwide, despite each condition being individually rare. Advances in genomics, CRISPR-Cas9 gene editing, and high-throughput drug screening have created unprecedented opportunities to design targeted therapies, shifting the commercial paradigm in favor of rare disease investment.

Pharmaceutical companies are increasingly drawn to this market by orphan drug designations and incentives such as market exclusivity, tax credits, and accelerated regulatory pathways offered by agencies like the U.S. FDA, EMA, and Japan’s PMDA. These incentives have stimulated significant activity in the development of therapies for conditions such as Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), Fabry disease, Gaucher disease, and Rett syndrome. Breakthrough approvals like Zolgensma (gene therapy for SMA) and Evrysdi (SMN2 splicing modulator) exemplify how targeted innovation can address previously untreatable conditions.

_How Are Novel Modalities and Precision Approaches Transforming Treatment?_

The treatment landscape for rare genetic disorders is being reshaped by gene therapy, antisense oligonucleotides (ASOs), and enzyme replacement therapies (ERTs). Gene therapies-such as AAV-mediated delivery systems-offer one-time, potentially curative interventions for monogenic disorders. These therapies are expanding into broader indications like hemophilia A/B and metabolic syndromes, supported by scalable manufacturing platforms and deeper mechanistic understanding of genetic expression.

ASOs, such as those used in treating SMA and Batten disease, provide personalized treatments tailored to individual mutations. These agents modify splicing or gene transcription to restore deficient protein production, offering hope in conditions where traditional small molecules have failed. Meanwhile, ERTs continue to dominate in lysosomal storage disorders, with newer formulations exhibiting improved biodistribution and reduced immunogenicity.

Another notable advancement is the use of patient-derived induced pluripotent stem cells (iPSCs) and organoid models for preclinical drug testing. These enable personalized medicine approaches that align with the mutation-specific etiology of many rare diseases. Clinical trial design is also being revolutionized through basket trials, n-of-1 studies, and natural history data integration-tailored to the small, dispersed nature of rare disease populations.

Which Therapeutic Areas and Stakeholders Are Leading the Push?

Neurological and metabolic genetic disorders represent the highest concentration of innovation and investment. Conditions such as Huntington’s disease, SMA, and Leber congenital amaurosis are targets for gene therapy pipelines, while ERTs continue to dominate the treatment of Gaucher, Pompe, and Fabry diseases. Pediatric indications are particularly prominent, as early diagnosis and intervention are crucial for reducing disease burden and improving quality of life.

Biopharmaceutical companies specializing in rare diseases-such as BioMarin, Sarepta, Ultragenyx, and Spark Therapeutics-are leading clinical and commercial progress. These firms are often supported by nonprofit foundations, academic research networks, and patient advocacy groups that help drive trial recruitment and regulatory engagement. Global patient registries and rare disease consortia are increasingly being used to standardize data collection, validate endpoints, and justify accelerated approvals.

Geographically, North America and Europe remain dominant in drug development and regulatory activity, thanks to mature healthcare systems, funding ecosystems, and favorable policy frameworks. However, Asia-Pacific is seeing rapid momentum, particularly in gene editing research and biologics manufacturing capabilities, positioning it as a future growth frontier for rare genetic therapies.

What Is Driving Growth in the Rare Genetic Disorders Treatment Market?

The growth in the rare genetic disorders treatment market is driven by the convergence of scientific innovation, regulatory incentives, and increasing diagnosis rates enabled by genomic testing. As whole-genome sequencing becomes more accessible and affordable, previously undiagnosed or misdiagnosed conditions are being accurately classified, expanding the eligible treatment population. This diagnostic clarity is critical for precision medicine approaches like ASOs and gene therapy.

Regulatory frameworks such as the Orphan Drug Act (USA), PRIME (EU), and Sakigake designation (Japan) are accelerating time-to-market for novel therapies. These policies reduce development risk, attract investment, and foster innovation through fast-track designations, smaller trial requirements, and longer exclusivity windows. Simultaneously, payer willingness to reimburse high-cost, high-impact treatments-often justified by long-term cost offsets-has strengthened the commercial viability of these therapies.

Collaborative ecosystems involving biotech firms, patient advocacy organizations, and regulatory bodies are ensuring that research is patient-centered and outcome-oriented. As digital health platforms and telemedicine expand, especially in post-approval patient monitoring and real-world evidence generation, the rare genetic disorders treatment market is positioned to evolve from niche to normalized care-redefining the future of personalized medicine.

SCOPE OF STUDY:

The report analyzes the Rare Genetic Disorders Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Biologics & Biosimilars, Non-Biologics); Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy); Application (Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application, Metabolic Disorders Application, Hematology Diseases Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • Alexion (AstraZeneca Rare Disease)
  • Amicus Therapeutics
  • Arcturus Therapeutics
  • Beacon Therapeutics
  • BioMarin Pharmaceutical
  • Bluebird Bio
  • CRISPR Therapeutics
  • Genomic startups (e.g., GeneQuine)
  • PTC Therapeutics
  • ProQR Therapeutics
  • Rocket Pharmaceuticals
  • Sarepta Therapeutics
  • Spark Therapeutics
  • Translate Bio (Sanofi)
  • Tune Therapeutics
  • Ultragenyx Pharmaceutical
  • Vertex Pharmaceuticals
  • Zygnema/Airna etc. (RNA-editing)
  • Glycomine
  • Calliditas Therapeutics
  • Ipsen

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Rare Genetic Disorders Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Acceleration of Gene and Cell Therapy Approvals Throws the Spotlight On Rare Genetic Disorder Treatments
    • Rising Orphan Drug Designations Drive R&D Investment and Market Exclusivity Opportunities
    • Innovation in mRNA, CRISPR, and AAV-Based Therapies Expands the Genetic Treatment Toolbox
    • Surge in Patient Advocacy and Rare Disease Registries Enhances Disease Awareness and Diagnosis Rates
    • Partnerships With Biotech Startups Strengthen Clinical Pipelines in Niche Genetic Indications
    • Growth in Precision Medicine Initiatives Supports Development of Mutation-Specific Therapies
    • Expansion of Newborn Screening and Genomic Panels Promotes Early Intervention in Rare Conditions
    • Increased Payer Willingness to Reimburse High-Cost Therapies Strengthens Commercial Viability
    • Focus on Single-Dose and Long-Term Cure Modalities Drives Differentiation in Product Profiles
    • Rising Incidence of Ultra-Rare and Undiagnosed Disorders Expands Addressable Patient Subsets
    • Strategies for Companion Diagnostic Integration Improve Treatment Matching and Patient Selection
    • Growth in Global Regulatory Harmonization for Orphan Drugs Speeds Time-to-Market in Emerging Economies
    • Use of Expanded Access and Compassionate Use Programs Builds Clinical Experience and Evidence
    • Increased Investment From Venture Capital and Nonprofit Consortia Boosts Innovation Funding
    • Development of AI Tools for Variant Interpretation and Therapy Matching Enhances Discovery
    • Surge in Academic-Industry Collaborations Supports Translational Research Across Rare Pathologies
    • Participation in Basket and Umbrella Trials Enables Efficient Testing Across Multiple Mutations
    • Rising Role of Cell Banks and Biorepositories Enhances Research Infrastructure and Target Validation
    • Commitment to Lifecycle Management and Post-Market Data Collection Supports Long-Term Safety Monitoring
    • Policy Support for Personalized and Value-Based Reimbursement Models Expands Market Access Pathways
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rare Genetic Disorders Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Rare Genetic Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Biologics & Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Biologics & Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Non-Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hematology Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hematology Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Neurological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Neurological Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Cardiovascular Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Cardiovascular Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Metabolic Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Metabolic Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Hospitals Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rare Genetic Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Drug Type - Biologics & Biosimilars and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Rare Genetic Disorders Treatment by Drug Type - Percentage Breakdown of Value Sales for Biologics & Biosimilars and Non-Biologics for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Application - Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Rare Genetic Disorders Treatment by Application - Percentage Breakdown of Value Sales for Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Distribution Channel - Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Rare Genetic Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Drug Type - Biologics & Biosimilars and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Rare Genetic Disorders Treatment by Drug Type - Percentage Breakdown of Value Sales for Biologics & Biosimilars and Non-Biologics for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Application - Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Rare Genetic Disorders Treatment by Application - Percentage Breakdown of Value Sales for Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Distribution Channel - Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Rare Genetic Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2025 & 2030
  • JAPAN
    • Rare Genetic Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Drug Type - Biologics & Biosimilars and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Rare Genetic Disorders Treatment by Drug Type - Percentage Breakdown of Value Sales for Biologics & Biosimilars and Non-Biologics for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Application - Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Rare Genetic Disorders Treatment by Application - Percentage Breakdown of Value Sales for Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Distribution Channel - Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Rare Genetic Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2025 & 2030
  • CHINA
    • Rare Genetic Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Drug Type - Biologics & Biosimilars and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Rare Genetic Disorders Treatment by Drug Type - Percentage Breakdown of Value Sales for Biologics & Biosimilars and Non-Biologics for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Application - Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Rare Genetic Disorders Treatment by Application - Percentage Breakdown of Value Sales for Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Distribution Channel - Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Rare Genetic Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2025 & 2030
  • EUROPE
    • Rare Genetic Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Rare Genetic Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Drug Type - Biologics & Biosimilars and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Rare Genetic Disorders Treatment by Drug Type - Percentage Breakdown of Value Sales for Biologics & Biosimilars and Non-Biologics for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Application - Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Rare Genetic Disorders Treatment by Application - Percentage Breakdown of Value Sales for Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Distribution Channel - Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Rare Genetic Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2025 & 2030
  • FRANCE
    • Rare Genetic Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Drug Type - Biologics & Biosimilars and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Rare Genetic Disorders Treatment by Drug Type - Percentage Breakdown of Value Sales for Biologics & Biosimilars and Non-Biologics for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Application - Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Rare Genetic Disorders Treatment by Application - Percentage Breakdown of Value Sales for Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Distribution Channel - Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Rare Genetic Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2025 & 2030
  • GERMANY
    • Rare Genetic Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Drug Type - Biologics & Biosimilars and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Rare Genetic Disorders Treatment by Drug Type - Percentage Breakdown of Value Sales for Biologics & Biosimilars and Non-Biologics for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Application - Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Rare Genetic Disorders Treatment by Application - Percentage Breakdown of Value Sales for Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Distribution Channel - Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Rare Genetic Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2025 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Drug Type - Biologics & Biosimilars and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Rare Genetic Disorders Treatment by Drug Type - Percentage Breakdown of Value Sales for Biologics & Biosimilars and Non-Biologics for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Application - Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Rare Genetic Disorders Treatment by Application - Percentage Breakdown of Value Sales for Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Distribution Channel - Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Rare Genetic Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2025 & 2030
  • UNITED KINGDOM
    • Rare Genetic Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Drug Type - Biologics & Biosimilars and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Rare Genetic Disorders Treatment by Drug Type - Percentage Breakdown of Value Sales for Biologics & Biosimilars and Non-Biologics for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Application - Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Rare Genetic Disorders Treatment by Application - Percentage Breakdown of Value Sales for Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Distribution Channel - Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Rare Genetic Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Drug Type - Biologics & Biosimilars and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Rare Genetic Disorders Treatment by Drug Type - Percentage Breakdown of Value Sales for Biologics & Biosimilars and Non-Biologics for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Application - Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Rare Genetic Disorders Treatment by Application - Percentage Breakdown of Value Sales for Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Distribution Channel - Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Rare Genetic Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Rare Genetic Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Drug Type - Biologics & Biosimilars and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Rare Genetic Disorders Treatment by Drug Type - Percentage Breakdown of Value Sales for Biologics & Biosimilars and Non-Biologics for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Application - Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Rare Genetic Disorders Treatment by Application - Percentage Breakdown of Value Sales for Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Distribution Channel - Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Rare Genetic Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Drug Type - Biologics & Biosimilars and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Rare Genetic Disorders Treatment by Drug Type - Percentage Breakdown of Value Sales for Biologics & Biosimilars and Non-Biologics for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Application - Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Rare Genetic Disorders Treatment by Application - Percentage Breakdown of Value Sales for Hematology Diseases Application, Other Applications, Cancer Application, Neurological Disorders Application, Cardiovascular Diseases Application and Metabolic Disorders Application for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Rare Genetic Disorders Treatment by Distribution Channel - Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Rare Genetic Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2025 & 2030

IV. COMPETITION